IQ Webinar Series: 4β-hydroxycholesterol Working Group (DMLG and CPLG)
Join us for the 4β-hydroxycholesterol Working Group (DMLG and CPLG) webinar on Apr 29, 2016 at 11:00 AM EDT.
Plasma 4β-hydroxycholesterol (4β-HC) is considered as an emerging endogenous hepatic CYP3A biomarker. In this webinar, the scope of 4β-HC working group will be shared. Various bioanalytical approaches for 4β-HC quantification, the biology of 4β-HC, its response to treatment with CYP3A inducers, inhibitors and mixed inducer/inhibitors in healthy volunteers and patients, the association of 4β-HC with other probes of CYP3A activity (e.g., midazolam, urinary cortisol ratios), and predictive pharmacokinetic models will be reviewed in details. We will provide recommendations to study the hepatic CYP3A activity in clinical pharmacology studies utilizing 4β-HC at different stages of drug development.
After registering, you will receive a confirmation email containing information about joining the webinar.